The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling ...

Managing obesity with both drugs and lifestyle changes ‘enables clinicians to treat patients holistically, long-term, and in ...

Medicare coverage will cut obesity-drug prices but open the door to millions of new patients.

Pfizer noted it has completed its acquisition of all outstanding shares of the company’s common stock for $65.60 per share in ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

Eli Lilly and Novo Nordisk's competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh.

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...

Trump's deal slashes GLP-1 drug costs for Medicare beneficiaries and others, unlocking coverage for millions with obesity and ...

Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare ...